<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036998</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069347</org_study_id>
    <secondary_id>CELSION-10200202</secondary_id>
    <secondary_id>OU-09532</secondary_id>
    <nct_id>NCT00036998</nct_id>
  </id_info>
  <brief_title>Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer</brief_title>
  <official_title>A Randomized Pivotal Clinical Trial In Breast Cancer Patients Of Pre-Operative Focal Microwave Thermotherapy Treatment For Early-Stage Breast Disease In Intact Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celsion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Microwave thermotherapy kills tumor cells by heating them to several degrees above&#xD;
      body temperature.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of microwave thermotherapy&#xD;
      before surgery to that of surgery alone in treating women who have stage I or stage II breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the safety and efficacy of preoperative focused microwave thermotherapy followed&#xD;
           by surgery vs surgery alone in women with early-stage primary breast cancer.&#xD;
&#xD;
        -  Compare the reduction of tumor cells at surgical margins and second incision rates in&#xD;
           women treated with these regimens.&#xD;
&#xD;
        -  Compare the percentage of pathological cell death in women treated with these regimens.&#xD;
&#xD;
        -  Compare the amount of surgically removed breast and tumor tissue in women treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Compare the measurement of the extent tumor margins of the surgically removed breast and&#xD;
           tumor tissue in women treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to tumor classification (T1 vs T2) and participating center. Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I:Patients undergo ultrasound-guided placement of a microwave sensor and a&#xD;
           temperature probe (before or after compression of the breast) and external placement of&#xD;
           2 large opposing microwave emitters and up to 7 skin temperature sensors on the&#xD;
           compressed breast. Patients then receive focused microwave thermotherapy that slowly&#xD;
           heats the primary breast tumor and deep proximal breast tissue. In the absence of undue&#xD;
           heating of the skin, a tumor temperature of 48-52Â° C is targeted and maintained for an&#xD;
           equivalent thermal dose of 140-180 minutes.&#xD;
&#xD;
      Within 60 days of thermotherapy, patients undergo lumpectomy.&#xD;
&#xD;
        -  Arm II: Patients undergo lumpectomy only. Patients are followed at 30 and 90 days after&#xD;
           surgery, and then at the discretion of the physician.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 200-222 patients (100-111 per treatment arm) will be accrued&#xD;
      for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2001</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thermal ablation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary breast cancer by core needle biopsy&#xD;
&#xD;
               -  T1a, b, c, or T2&#xD;
&#xD;
               -  Diagnosis not made with a lumpectomy or incisional biopsy&#xD;
&#xD;
          -  Candidate for breast conservation surgery (lumpectomy/radiotherapy)&#xD;
&#xD;
          -  Tumor measurable by breast ultrasound&#xD;
&#xD;
          -  No metastatic disease, including skin metastases&#xD;
&#xD;
          -  No bilateral breast cancer&#xD;
&#xD;
          -  No high-probability of extensive intraductal disease in situ&#xD;
&#xD;
          -  No clinical fixation to the pectoralis major muscle or skin&#xD;
&#xD;
          -  No involvement of the nipple&#xD;
&#xD;
          -  No inflammatory breast cancer&#xD;
&#xD;
          -  No multicentric disease&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (no thrombocytopenia)&#xD;
&#xD;
          -  No bleeding disorders&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT, INR, and PTT less than 1.5 times normal&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Transaminases no greater than 2 times normal&#xD;
&#xD;
          -  No coagulopathy&#xD;
&#xD;
          -  No liver disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN less than 30 mg/dL&#xD;
&#xD;
          -  Creatinine less than 1.9 mg/dL&#xD;
&#xD;
          -  No renal insufficiency&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No pacemakers or defibrillators&#xD;
&#xD;
          -  No clinically significant heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 forms of effective contraception, including 1 barrier&#xD;
             method&#xD;
&#xD;
          -  Able to tolerate prone position and breast compression&#xD;
&#xD;
          -  No breast implants&#xD;
&#xD;
          -  No prior collagen vascular disease&#xD;
&#xD;
          -  No other factor or condition (other than tumor size) that would preclude lumpectomy&#xD;
&#xD;
          -  No mental condition that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior participation in this study&#xD;
&#xD;
          -  More than 30 days since prior participation in another clinical study&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William E. Gannon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Celsion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital Regional Cancer Center - Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Breast Center of Coral Springs</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Medical Center at University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mroz-Baier Breast Care Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breast Care Specialists, P.C.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bolton Hospital</name>
      <address>
        <city>Bolton, Lancashire</city>
        <state>England</state>
        <zip>BL4 0JR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

